Creyon Bio appoints venture capitalists to board in September 2024

Creyon Bio, Inc., a leader in AI/machine learning for oligonucleotide-based medicines, has appointed Serge Messerlian and Shaquille Vayda to its Board of Directors as of September 9, 2024. Messerlian, with a strong background in life sciences, has held leadership roles in various therapeutic areas and brings experience from his time as CEO of Teon Therapeutics and President of Janssen Oncology. Vayda, who has a diverse background in technology and life sciences, has worked at Illumina and Lux Capital, focusing on innovative platforms and tools in the industry. The appointments are expected to enhance Creyon's mission of transforming drug development through advanced engineering techniques. Messerlian expressed enthusiasm about the potential applications of Creyon's technology, which aims to shift the paradigm from traditional drug discovery to a more efficient drug engineering process. Vayda highlighted the company's commitment to revolutionizing the safety and targeted delivery of oligonucleotide-based medicines. Creyon Bio is recognized for its unique platform that prioritizes safety in the engineering of oligonucleotide-based medicines, including antisense oligonucleotides, siRNAs, and aptamers. This innovative approach is set to change how novel OBMs are created, ensuring optimal pharmacological properties and effective targeting of cells and tissues. The addition of Messerlian and Vayda to the board signifies a strategic move to leverage their extensive expertise in life sciences and technology, which is crucial for advancing Creyon's objectives in the rapidly evolving field of drug development.